<DOC>
	<DOC>NCT00693693</DOC>
	<brief_summary>The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.</brief_summary>
	<brief_title>Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis</brief_title>
	<detailed_description>An investigator-blinded prospective study of subjects with mild to moderate atopic dermatitis (&gt;5% Body Surface area and 2 or 3 on the Investigator Global Assessment (IGA) scale). The drug will be used within FDA-approved labeling. Approximately 30 male and female adults age ≥18 years will be enrolled through informed consent. Subjects will be asked to participate in helping us determine how well Locoid® works for atopic dermatitis. Adherence will be measured by MEMs cap.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<mesh_term>Hydrocortisone-17-butyrate</mesh_term>
	<criteria>Male or female ≥ 18 years of age. Subjects must have diagnosis of mild to moderate atopic dermatitis using IGA criteria. (2 or 3 on severity scale) Subjects must have &gt;5% TBSA and &lt;30% to be enrolled. Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control. Known allergy or sensitivity to topical Locoid® cream, ointment or lipocream in the subject. Inability to complete all studyrelated visits. Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Requiring &gt;130 gm of cream in a 2 week period. Having facial or groin involvement of their disease. Pregnant women and women who are breast feeding are to be excluded. Women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>